Market Research Logo

Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, rising healthcare expenditure, and increased access to medical insurance in developed countries are driving growth in the caner immunotherapy market. However, stringent regulatory policies and side-effects associated with cancer therapy are the major factors restraining the growth of this market.

The global cancer immunotherapy market has been segmented on the basis of type, application, end user, and region. The monoclonal antibodies segment is expected to register the highest growth rate in the cancer immunotherapy market, by type, during the forecast period. Factors such as high success rate and less recovery time are contributing to the high growth in this segment.

Based on application, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others (renal cell carcinoma, cervical, gastric, and lymphoma). The lung cancer segment is expected to witness the highest CAGR from 2016 to 2021, primarily due to the rising prevalence of this type of cancer.

Based on end users, the global cancer immunotherapy market is segmented into hospitals and clinics & others. The hospitals segment is expected to account for the largest share of the global cancer immunotherapy market in 2016. The rise in healthcare spending has resulted in the increasing use of drugs in hospitals.

Geographically, the cancer immunotherapy market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). The large share of North America can be attributed to the growing aging population and the increased funding from government and non-government agencies in order to increase the research capacity.

Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output, in order to remain successful in the cancer immunotherapy market.

The major players in the cancer immunotherapy market include Amgen (U.S.), AstraZeneca (U.K.), F. Hoffman La-Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).

OBJECTIVES OF THE STUDY
To define, describe, and forecast the global cancer immunotherapy market on the basis of type, application, end user, and region
To provide detailed information regarding the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the global cancer immunotherapy market
To strategically analyze the markets with respect to their individual growth trends, future prospects, and contributions to the total market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the revenue of market segments with respect to four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
To profile the key players and comprehensively analyze their market shares and core competencies
To analyze competitive developments such as new product launches; agreements, partnerships, and joint ventures; mergers & acquisitions; and R&D activities in the global cancer immunotherapy market

Target Audience for this Report:
Drug Manufacturers and Suppliers
Academic Research Institutes
Hospitals and Clinics
Research and Development (R&D) Companies
Business Research and Consulting Service Providers
Medical Research Laboratories
Academic Medical Centers and Universities

Scope of the Report:
In this report, the cancer immunotherapy market has been segmented into the following segments and subsegments:
Cancer Immunotherapy Market, by Type
Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
Cancer Immunotherapy Market, by Application
Lung Cancer
Breast Cancer
Head and Neck Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Others
Cancer Immunotherapy Market, by End User
Hospitals
Clinics & Others
Cancer Immunotherapy Market, by Region
North America
U.S.
Canada
Europe
Germany
France
Italy
U.K.
Spain
RoE
APAC
India
China
Japan
RoAPAC
Rest of the World (RoW)
South America, Central America, and the Caribbean
Oceania
Africa


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
    • MARKETS COVERED
      • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • STAKEHOLDERS
  • RESEARCH METHODOLOGY
    • MARKET SIZE ESTIMATION
    • MARKET BREAKDOWN AND DATA TRIANGULATION
    • MARKET SHARE ESTIMATION
      • KEY DATA FROM SECONDARY SOURCES
      • KEY DATA FROM PRIMARY SOURCES
    • ASSUMPTIONS FOR THE STUDY
  • EXECUTIVE SUMMARY
    • INTRODUCTION
    • CURRENT SCENARIO
    • FUTURE OUTLOOK
  • PREMIUM INSIGHTS
    • LUCRATIVE OPPORTUNITIES IN THE CANCER IMMUNOTHERAPY MARKET
  • MARKET OVERVIEW
    • INTRODUCTION
      • DRIVERS
      • RESTRAINTS
      • OPPORTUNITIES
      • CHALLENGES
    • OVERVIEW OF GLOBAL CANCER IMMUNOTHERAPY FUNDING
      • Table OVERVIEW OF FUNDING PATTERN IN DIFFERENT TYPES OF CANCER BY NIH, U.S., 2012-2017 (USD MILLION)
      • Table OVERVIEW OF KEY FUNDING IN CANCER IMMUNOTHERAPY MARKET, 2016
      • Table CONVENTIONAL CANCER THERAPY VERSUS CANCER IMMUNOTHERAPY
  • INDUSTRY TRENDS
    • GLOBAL TRENDS IN CANCER IMMUNOTHERAPY MARKET
      • OPDIVO (NIOLUMAB) AND KEYTRUDA (PEMBROLIZUMAB) FDA APPROVAL IN U.S. INCREASES HOPE AMONGST LUNG CANCER PATIENTS
      • COMBINATION IMMUNOTHERAPY POTENTIAL WAY TO TREAT MELANOMA
      • U.S. CANCER IMMUNOTHERAPY RESEARCH COMMUNITY BUILDS HOPE TO COMBAT CANCER BY 2020
      • U.K. SCIENTISTS PROJECT A CHANGE IN THE MEANS OF TREATMENT FOR CANCER WITH QUALITY THERAPIES
      • WORLD IS MOVING TOWARD PERSONALIZED IMMUNOTHERAPY
      • A COMBINATION OF MODERN IMMUNOTHERAPY AND TRADITIONAL CHINESE MEDICINES CONTINUES TO INCREASE SURVIVAL RATE OF PATIENTS IN CHINA
    • PRICING VARIATIONS IN GLOBAL CANCER IMMUNOTHERAPY MARKET
    • SMALL PLAYERS GETTING TOGETHER TO MAKE LONG TERM IMPACT IN CANCER IMMUNOTHERAPY MARKET
    • ATTRACTIONS FOR PHARMACEUTICAL INDUSTRY
    • HEAT MAP FOR VARIATIONS IN CANCER IMMUNOTHERAPY FOR DIFFERENT TYPES OF CANCERS
      • BREAST CANCER
      • LUNG CANCER
      • MULTIPLE MYELOMA
      • LYMPHOMA
  • CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE
    • INTRODUCTION
      • Table CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
    • MONOCLONAL ANTIBODIES
      • Table CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBTYPE, 2014-2021 (USD MILLION)
      • Table CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION, 2014-2021 (USD MILLION)
      • NAKED MONOCLONAL ANTIBODIES
        • Table NAKED MONOCLONAL ANTIBODIES MARKET, BY REGION, 2014-2021 (USD MILLION)
      • CONJUGATED MONOCLONAL ANTIBODIES
        • Table CONJUGATED MONOCLONAL ANTIBODIES MARKET, BY REGION, 2014-2021 (USD MILLION)
      • BISPECIFIC MONOCLONAL ANTIBODIES
        • Table BISPECIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • VACCINES
      • Table VACCINES MARKET, BY SUBTYPE, 2014-2021 (USD MILLION)
      • Table VACCINES MARKET, BY REGION, 2014-2021 (USD MILLION)
      • PROPHYLACTIC VACCINES
        • Table PROPHYLACTIC VACCINES MARKET SIZE, 2014-2021 (USD MILLION)
      • THERAPEUTIC VACCINES
        • Table THERAPEUTIC VACCINES MARKET, BY REGION, 2014-2021 (USD MILLION)
    • CHECK POINT INHIBITORS
      • Table CHECKPOINT INHIBITORS MARKET SIZE, BY SUBTYPE, 2014-2021 (USD MILLION)
      • Table CHECKPOINT INHIBITORS MARKET, BY REGION, 2014-2021 (USD MILLION)
      • CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4)
        • Table CYTOXIC T-LYMPHOCYTE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
      • PROGRAMMED DEATH 1 (PD-1) AND PROGRAMMED DEATH LIGAND 1 (PD-L1)
        • Table CYTOXIC T-LYMPHOCYTE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • CELL THERAPIES
      • CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
      • DENDRITIC CELLS
    • IMMUNOMODULATORS
      • Table IMMUNOMODULATORS MARKET SIZE, BY SUBTYPE, 2014-2021 (USD MILLION)
      • Table IMMUNOMODULATORS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
      • GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF & G-CSF)
        • Table GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
      • INTERFERONS (IFN)
        • Table INTERFERONS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
      • INTERLEUKINS (IL)
        • Table INTERLEUKINS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
      • ONCOLYTIC VIRUS
  • CANCER IMMUNOTHERAPY MARKET, BY APPLICATION
    • INTRODUCTION
      • Table CANCER IMMUNOTHERAPY MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
    • LUNG CANCER
      • Table LUNG CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • BREAST CANCER
      • Table BREAST CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • MULTIPLE MYELOMA
      • Table MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • COLORECTAL CANCER
      • Table COLORECTAL CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • HEAD & NECK CANCER
      • Table HEAD & NECK CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • PROSTATE CANCER
      • Table PROSTATE CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • MELANOMA
      • Table MELANOMA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • OTHER CANCER TYPES
      • Table OTHER TYPES OF CANCER MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • CANCER IMMUNOTHERAPY MARKET, BY END USER
    • INTRODUCTION
      • Table CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
    • HOSPITAL
      • Table HOSPITALS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • CLINICS AND OTHERS
      • Table CLINICS AND OTHERS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • CANCER IMMUNOTHERAPY MARKET, BY REGION
    • INTRODUCTION
      • Table CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
    • EUROPE
      • Table EUROPE: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
    • ASIA-PACIFIC
      • Table ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
    • REST OF THE WORLD (ROW)
      • Table ROW: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014-2021 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • OVERVIEW
    • MARKET SHARE ANALYSIS
    • COMPETITIVE SITUATION AND TRENDS
      • APPROVALS
        • Table APPROVALS, 2013-2016
      • AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
        • Table AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2013-2016
      • ACQUISITIONS
        • Table ACQUISITIONS, 2013-2016
      • EXPANSIONS
        • Table EXPANSIONS, 2013-2016
      • OTHER DEVELOPMENTS
  • COMPANY PROFILE
    • AMGEN INC.
      • BUSINESS OVERVIEW
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • ASTRAZENECA
      • BUSINESS OVERVIEW
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • BAYER AG
      • BUSINESS OVERVIEW
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • BRISTOL-MYERS SQUIBB
      • BUSINESS OVERVIEW
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • ELI LILLY AND COMPANY
      • BUSINESS OVERVIEW
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • JANSSEN GLOBAL SERVICES, LLC (JOHNSON AND JOHNSON)
      • BUSINESS OVERVIEW
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • MERCK
      • BUSINESS OVERVIEW
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • NOVARTIS
      • BUSINESS OVERVIEW
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • PFIZER
      • BUSINESS OVERVIEW
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MNM VIEW
    • F. HOFFMANN-LA ROCHE LTD
      • BUSINESS OVERVIEW
      • PRODUCT PORTFOLIO
      • RECENT DEVELOPMENTS
      • MNM VIEW
  • APPENDIX
    • INSIGHTS FROM INDUSTRY EXPERTS
    • DISCUSSION GUIDE
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
    • AVAILABLE CUSTOMIZATIONS
    • RELATED REPORTS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report